Clinical Research Directory
Browse clinical research sites, groups, and studies.
Identification of the Best Treatment Pathway for Patients With Relapsed/Refractory Lymphocytic B-derived Non-Hodgkin Lymphoma
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Summary
Bispecific antibodies have demonstrated high efficacy in the treatment of Refractory/relapsed b-cell non-Hodgkin lymphomas. However, a non-negligible percentage of patients do not respond to therapy and/or develop significant treatment toxicity.
Official title: Identification of the Best Treatment Pathway for Patients With Relapsed/Refractory Lymphocytic B-derived Non-Hodgkin Lymphoma, Through the Identification of Prognostic Factors and Mechanisms of Resistance to Bispecific Antibody Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
70
Start Date
2026-06-30
Completion Date
2028-12-31
Last Updated
2026-05-29
Healthy Volunteers
Not specified
Conditions
Locations (1)
IRCCS Policlinico di Sant'Orsola
Bologna, Emilia-Romagna, Italy